Source: Annual Congress 2003 - Miscellaneous problems in COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. E. Makarevich (Minsk, Russia). The aimful treatment of hemorheological disorders (HD) in COPD patients. Eur Respir J 2003; 22: Suppl. 45, 2726

Member's Comments

No comment yet.

Related content which might interest you: The types and frequency of mental disorders in COPD patients (pts) according to severity of COPD Source: International Congress 2017 – Extrapulmonary comorbidities in COPD Year: 2017 Impact of systemic inflammation on frequency and severityof mental disorders in COPD patients (pts) Source: Virtual Congress 2020 – Clinical and functional evaluation of COPD Year: 2020 The severity of anxiety in COPD patients (pts) Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016 Prediction of vascular-platelet hemostasis disorders in patients with chronic obstructive pulmonary disease (COPD) Source: Virtual Congress 2020 – Investigations of COPD Year: 2020 Differences between patients with overlap syndrome (COPD + OSAS) and patients with OSAS Source: International Congress 2015 – Measuring sleep-disordered breathing in children and adults I: questionnaires, epidemiology and sleep studies Year: 2015 The relationship between depression, medication and stage of the disease in patients with COPD Source: Annual Congress 2006 - COPD comorbidity Year: 2006 The impact of long-term conventional treatment for overlap syndrome (OSA and COPD) on concurrent erectile dysfuction (ED) Source: Eur Respir J 2006; 28: Suppl. 50, 198s Year: 2006 Baseline self-reported comorbidity in COPD patients referred for pulmonary rehabilitation (PR) Source: Annual Congress 2006 - COPD comorbidity Year: 2006 Can we predict the outcomes of treatment of patients with severe exacerbation of chronic obstructive pulmonary disease (COPD)? Source: Eur Respir J 2001; 18: Suppl. 33, 241s Year: 2001 Comparisons among various QOL assessments and clinical outcomes for one year in elderly patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2004; 24: Suppl. 48, 66s Year: 2004 Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes Source: International Congress 2015 – Different data in COPD Year: 2015 The prevalence and clinical characteristics of asthma–COPD overlap syndrome (ACOS) in patients with COPD Source: International Congress 2017 – COPD: from screening to risk factors of lung cancer Year: 2017 The beta-blockers in combined treatment of coronary heart disease in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2013 –COPD treatment Year: 2013 Regional differences in the treatment of patients with moderate COPD enrolled in a global clinical trial Source: Annual Congress 2006 - Recent advances in the treatment of COPD Year: 2006 Mental disorders in patients (pts) with COVID-19 pneumonia:comparison with COPD exacerbation Source: Virtual Congress 2021 – Long COVID - 19 Year: 2021 Increased prevalence of obstructive airways disease (OAD) in patients with ischemic heart disease (IHD) and hypertension (HT) Source: Eur Respir J 2007; 30: Suppl. 51, 122s Year: 2007 Impact of co-morbidities on the rehabilitation outcome in COPD patients Source: Annual Congress 2007 - Impact of comorbidities in pulmonary rehabilitation Year: 2007 The prevalence of chronic obstructive pulmonary disease (COPD) in individuals with diabetes, hypertension, asthma, or mood/anxiety disorders: A Canadian population study Source: Annual Congress 2012 - Asthma and COPD: quality of life and comorbidities Year: 2012 Increased oxidative stress in patients with chronic obstructive pulmonary disease (COPD) and metabolic syndrome (MetS) Source: Annual Congress 2013 –Translational studies in chronic lung diseases: from bedside to bench Year: 2013